0001651308-24-000005.txt : 20240123 0001651308-24-000005.hdr.sgml : 20240123 20240123060337 ACCESSION NUMBER: 0001651308-24-000005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240122 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240123 DATE AS OF CHANGE: 20240123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981209416 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 24550423 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 8-K 1 bgne-20240122.htm 8-K bgne-20240122
0001651308false00016513082024-01-222024-01-22



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 22, 2024

BEIGENE, LTD.
(Exact Name of Registrant as Specified in Charter)

Cayman Islands
001-37686
98-1209416
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of Principal Executive Offices) (Zip Code)
+1 (345) 949-4123
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
BGNE
The NASDAQ Global Select Market
Ordinary Shares, par value $0.0001 per share*
06160
The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Director Resignation

On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”). In connection with his resignation, Mr. Malley also resigned from the Audit Committee and the Scientific Advisory Committee of the Board. Mr. Malley served as a member of the Board since 2016. The decision by Mr. Malley to resign was not the result of any disagreement with respect to the operations, policies, or practices of the Company.

Appointment of New Director

On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy. Dr. Brandicourt will serve as a Class II director until the 2024 Annual General Meeting of Shareholders to be held in June 2024 and until his successor is duly elected and qualified, subject to his earlier resignation or removal. Dr. Brandicourt was also appointed to serve as a member of the Audit Committee of the Board.

Dr. Brandicourt, aged 67, is currently a Senior Advisor at Blackstone Life Sciences, a private equity segment of The Blackstone Group that invests within the life science sector. He joined Blackstone Life Sciences in 2019. Dr. Brandicourt currently serves on the boards of Alnylam Pharmaceuticals, Inc., a NASDAQ-listed commercial-stage biopharmaceutical company developing novel therapeutics based on RNAi; BenevolentAI S.A., a Euronext listed clinical-stage AI-enabled drug discovery company; and Dewpoint Therapeutics, Inc., a privately held condensate biotechnology company. He also serves as chair of the board of AvenCell Therapeutics, Inc., a privately held leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic engineered CAR-T cell therapies. Dr. Brandicourt has over 30 years of experience in the global pharmaceutical industry, including as a senior leader of three global pharmaceutical companies. From April 2015 to August 2019, Dr. Brandicourt served as Chief Executive Officer and a member of the board of directors of Sanofi S.A. Prior to Sanofi, he was the Chief Executive Officer and Chair of Bayer HealthCare AG from November 2013 to March 2015. From 2000 to 2013, Dr. Brandicourt served in various operational and managerial positions at Pfizer Inc., including as a member of the Executive Leadership Team and President and General Manager of the Emerging Markets and Established Products business units. During his tenure at Sanofi, Dr. Brandicourt was elected Chairman of the Board of Management of the Pharmaceutical Research and Manufacturers of America in 2019 and Vice-President of the European Federation of Pharmaceutical Industries and Associations, serving from 2017-2019. He is an Honorary Fellow of the Royal College of Physicians in London. Dr. Brandicourt studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine and holds a Master’s Degree in Biology from Paris XII University and an Advanced Degree in Cellular and Immunological Pathophysiology from the Paris Descartes University. We believe that Dr. Brandicourt’s extensive global operational, commercial and senior management experience in the healthcare sector qualifies him to serve on the Board.

Dr. Brandicourt will receive the same compensation and indemnification as the Company’s other independent directors, as described in the Company’s Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 27, 2023. In accordance with the Company’s Amended Independent Director Compensation Policy (the “Policy”) and the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the “2016 Plan”), the Company will grant Dr. Brandicourt share options valued at US$400,000, pro-rated in the first year of service, with an exercise price equal to the greater of (i) the fair market value of the Company’s ordinary shares on the date of grant and (ii) the average fair market value of the Company’s ordinary shares over the five trading days preceding the date of grant, in each case as determined in reference to the closing price of the Company’s American Depositary Shares (“ADSs”) on the NASDAQ Stock Market. Each ADS represents 13 ordinary shares. The share option will vest in full on the earlier of the first anniversary of date of grant or the date of the next annual meeting of shareholders, and in full upon death, disability or the occurrence of specified events in connection with a change of control of the Company. Dr. Brandicourt will also receive annual cash compensation of US$65,000 for his service as a director, and annual cash compensation of US$17,500 for his service as a member of the Audit Committee, each pro-rated in the first year of service, and reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and its committees. Additionally, Dr. Brandicourt will be entitled to future cash compensation and annual equity grants in accordance with the Policy and the 2016 Plan.

There are no arrangements or understandings between Dr. Brandicourt and any other person pursuant to which he was elected as a director, nor are there any transactions between Dr. Brandicourt and the Company that would be reportable under Item 404(a) of Regulation S-K.

A copy of the press release announcing the appointment of Dr. Brandicourt to the Board is attached hereto as Exhibit 99.1 and is incorporated herein by reference.




Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.Description
99.1Press release titled “BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors” issued by BeiGene, Ltd. on January 23, 2024
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL


Exhibit Index


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BEIGENE, LTD.
 
 
 
 
 
 
Date: January 23, 2024
By: 
/s/ Chan Lee        
 
Name:
Chan Lee
 
Title:
Senior Vice President, General Counsel





 EX-99.1 2 a20240123formxmalleyresign.htm EX-99.1 Document

Exhibit 99.1

BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
BASEL, Switzerland; BEIJING; and CAMBRIDGE, Mass. – (BUSINESS WIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board.
Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016.
“Dr. Brandicourt brings a wealth of global experience as we expand the perspective of BeiGene’s Board of Directors to include deep expertise in leading multinational growth companies, spearheading launches in a range of therapeutic areas and scaling into new geographies,” said John V. Oyler, Chairman, CEO and Co-Founder at BeiGene. “The Board looks forward to working with Dr. Brandicourt, who drove excellence as an outstanding leader for multiple global pharmaceutical brands, as we continue our evolution as a next-generation oncology innovator. Tom has been an invaluable member of the board with service dating back before the Company’s IPO. We thank him for his dedicated service and incredible contributions to BeiGene’s global success and wish him well.”
“I am pleased to join BeiGene’s Board and help advance the Company’s mission to bring innovative cancer medicines to more patients around the world,” said Dr. Brandicourt. “Through my decades of pharmaceuticals and medical leadership, I have committed my career to ensuring equitable global access to improve patient outcomes. It is an honor to serve alongside my fellow Board members who share my commitment to this goal.”
About Olivier Brandicourt
Olivier Brandicourt is a prominent executive in the pharmaceuticals industry with decades of management, medical and marketing experience. He is currently a Senior Advisor at Blackstone Life Sciences and a director of Alnylam Pharmaceuticals, Inc., BenevolentAI S.A., and Dewpoint Therapeutics, Inc. He also serves as chair of the board of AvenCell Therapeutics, Inc.
Prior to joining Blackstone Life Sciences, Dr. Brandicourt served as CEO and as a member of the board of directors of Sanofi S.A. from 2015 to 2019. Dr. Brandicourt was the CEO and chair of Bayer HealthCare AG from 2013 to 2015. From 2000 to 2013, Dr. Brandicourt held a series of leadership positions at Pfizer Inc., including as President and General Manager of Global Specialty Care, Global Primary Care and most recently of the Emerging Markets and Established Products business units. Dr. Brandicourt was part of the Pfizer Executive team from 2010 to 2013.
Dr. Brandicourt studied medicine in Paris, where he specialized in Infectious Diseases and Tropical Medicine, and holds a master’s degree in biology from Paris XII University and an advanced degree in cellular and immunological pathophysiology from the Paris Descartes University.
During his tenure at Sanofi, Dr. Brandicourt was elected Chairman of the Board of Management of the Pharmaceutical Research and Manufacturers of America and Vice President of the European Federation of Pharmaceutical Industries and Associations. He is an Honorary Fellow of the Royal College of Physicians in London.
The full Board of Directors list is available on the BeiGene website at https://www.beigene.com/our-company-and-people/leadership-and-board/#CorporateLeaders.



About BeiGene
BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, and Cambridge, U.S. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn and X (formerly known as Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the expected contributions of the new board member and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Investor ContactMedia Contact
Liza HeapesKyle Blankenship
+1 857-302-5663+1 667-351-5176
ir@beigene.commedia@beigene.com



 EX-101.SCH 3 bgne-20240122.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bgne-20240122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Entity File Number Entity File Number Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 bgne-20240122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 22, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 22, 2024
Entity Registrant Name BEIGENE, LTD.
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 94 Solaris Avenue, Camana Bay
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1108
Entity Address, Country KY
Written Communications false
Soliciting Material false
City Area Code (345)
Local Phone Number 949-4123
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol BGNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001651308
Amendment Flag false
Entity Tax Identification Number 98-1209416
Entity File Number 001-37686
XML 7 bgne-20240122_htm.xml IDEA: XBRL DOCUMENT 0001651308 2024-01-22 2024-01-22 0001651308 false 8-K 2024-01-22 BEIGENE, LTD. E9 001-37686 98-1209416 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY (345) 949-4123 false false false false American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share BGNE NASDAQ false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '(P-U@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !R,#=8E?4%%^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VG40^CVHGA2$%Q0O(5D=C?8-"$9:??M3>MN%]$'\)B9/]]\ M ].:J$Q(^)Q"Q$0.\]7D^R$K$S?L0!050#8']#K7)3&4YBXDKZD\TQZB-A]Z MC]!P?@L>25M-&F9@%5S1XT 91"V =?/$ M>)SZ%BZ &4:8?/XNH%V)2_5/[-(!=DI.V:VI<1SK42ZYLH. MZ?'EV7=R@V9 M]&"P_,I.T3'BAITGO\J[^^T#ZQK>7%=<5(W<"J&X5/+F?7;]X7<1]L&ZG?O' MQF?!KH5?=]%] 5!+ P04 " !R,#=8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M '(P-UB/\[RD:@0 +,0 8 >&PO=V]R:W-H965T&UL MI9AA<^(V$(;_BL;M=.YF(-C&(7 %9H"0E":7T$![<^WT@[ %:,Z6?)(S+S,1-:(A:ST%@)"C_/;,+BV"H!Q_>CJ%-\TP:> M7K^JW^2=A\ZLJ&83&7_AD=D.G*Y#(K:F66R>Y.X7=NS0I=4+9:SSOV1W>#<( M'!)FVLCD& P$"1>'7_IR'(B3@*Y[)L _!O@Y]^%#.>4U-7385W)'E'T;U.Q% MWM4\&N"XL+.R, J>S_IE(9LX$!Z:J:>F3/\ MZ0>OX_Z,\+4+OC:F/KR680:Y:,ARG[(J.#R\V[Q#((("(G@;Q)PI+B,R%1&! M2:_DP96*Z:N;O\L"[1(5G K#S9X\L0VW,PB,#S2I!,-UQM/9[?1AVB#WR^L+ MA*M3<'7>PC43H52I5-0Z08,L#(P:D8I,9":,VL-O5 E;(]Y#"*\*PJNW$(ZB M"+)6-UXOR#V\1QY%)1:NV O(0L94<4U&STQDK$$F-*&"DC'=(\3=@KC[+N*) M;<%@+N5.5-'B:K>0+1$ [H$0@>L5<+UWP4IG=_#O3M/[Q'L>,XF4(W AW9P M^1%#*?W?PVW[7H:0R_.M!&MXR)+5FG%)1F1 U@G5)ZI?UP<=M_8@V@=Q18#TS6#LOY(Y50^%2 M-JTZEUX;+:7^R8$!-WA(>A'E"_LFIIM*GO]7(?RR0OBXP1\':4E?R"RRJVQ] M+*2(2==(]KI-SW=[@=?!",O"X>.>?R2\X3%6.&I$8/Z:[:M.MQ*I=7($MW$%OJ\.)^1#P\@T/Y6NI($S;GZY912LV;X S]=2FM>&/>@6 M_Z<8_@-02P,$% @ QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1< M>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6 ME :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,H MH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+ M3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC M%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8 M\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W M5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76 M^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1G MA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ M;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^: M0ERHY_U=3_ 102P,$% @ *NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:> MIK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DH MV1%[A$O\G7D(GP&LK M\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N M5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!Y MU!Y:YU;*O8=7LN48Y0]02P,$% @ FZ*M ^ $ !H M !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL M[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C] MLCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP M3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( '(P-UAED'F2&0$ ,\# M 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@ M"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0" M50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M- M\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[ M0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TF MGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( '(P-UB/\[RD:@0 +,0 8 " @0T( M !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " !R,#=899!YDAD! #/ P $P M@ &W$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !% " ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.beigene.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bgne-20240122.htm bgne-20240122.xsd bgne-20240122_lab.xml bgne-20240122_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bgne-20240122.htm": { "nsprefix": "bgne", "nsuri": "http://www.beigene.com/20240122", "dts": { "inline": { "local": [ "bgne-20240122.htm" ] }, "schema": { "local": [ "bgne-20240122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "bgne-20240122_lab.xml" ] }, "presentationLink": { "local": [ "bgne-20240122_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://www.beigene.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bgne-20240122.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bgne-20240122.htm", "first": true, "unique": true } } }, "tag": { "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCountry", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.beigene.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001651308-24-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651308-24-000005-xbrl.zip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end